IGF1R and non-small cell lung carcinoma: However, a phase-III study with an anti-IGF1R antibody combined with erlotinib in advanced non-small-cell lung cancer was terminated recently for safety reasons and lack of efficiency (ClinicalTrials.gov Identifier: NCT00673049).